Rodexo
Health Care

Third quarter sales beat forecasts as Ocrevus shines


The headquarters of Roche AG in Basel, Switzerland.

Gianluca Colla | Bloomberg | Getty Images

The headquarters of Roche AG in Basel, Switzerland.

Roche’s third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus,
the Swiss drugmaker said on Thursday.

Roche third-quarter sales were 13.1 billion Swiss francs ($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter.



Source : CNBC

Related posts

High cholesterol levels could increase stroke and heart attack risk | Health | Life & Style

Rodexo

Comment: My mental health and a journey to hell and back

Rodexo

Ban on assisted dying at St. Martha’s hospital should end, says law prof

Rodexo

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.